A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV).

Vanderbilt University Medical Center (VUMC) has received a two-year, $1.2 million award from the Tennessee Department of Health and Centers for Medicare and Medicaid Services to provide tailored education and coaching to 75 Middle Tennessee nursing homes focused on infection control, quality improvement and other pandemic-related challenges.

Paige Vega, a PhD student in the Department of Cell and Developmental Biology at Vanderbilt University, has been selected as the 2021 Vanderbilt Prize Student Scholar.

Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.